What the MHRA's Draft Medical Devices (Amendment) Regulations 2026 Mean for Manufacturers
On 11 May 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) published the draft Medical Devices (Amendment) Regulations 2026 - the most substantial rewrite of the UK Medical Devices Regulations 2002 since the country left the EU regulatory system. The draft Regulations were notified to the WTO on 8 May 2026. The MHRA stakeholder impact survey closed on 19 June 2026, while the WTO comment period ran until 7 July 2026.
The reforms are intended to strengthen patient safety, support innovation and improve access to medical technologies while creating more proportionate routes to market.
Importantly, the emerging GB framework should not be viewed simply as a transition from CE marking to a UKCA-only system. Alongside development of the UK's domestic regulatory framework, the government has been consulting on the indefinite recognition of CE-marked devices compliant with the EU MDR and IVDR, while also proposing new international reliance routes for certain devices.
This white paper summarises the five changes with the greatest commercial impact, situates them against parallel developments in the EU, US and India, and sets out a practical readiness checklist for regulatory and quality teams.
Why This Matters Now
Since Brexit, Great Britain has operated under a combination of UK-specific requirements, transitional arrangements and recognition of CE-marked devices.
The UK government is now implementing a broader programme of medical device regulatory reform. This includes development of new pre-market requirements, enhanced post-market surveillance provisions and consideration of longer-term arrangements for recognising CE-marked devices.
This means that the emerging UK system is best understood not as a simple replacement of CE with UKCA, but as a distinct GB regulatory framework incorporating multiple routes to market.
For manufacturers, the strategic question is therefore no longer simply:
"Do we need UKCA?"
It is increasingly:
"Which GB route to market is most appropriate for our device, and how will the UK requirements interact with our existing EU, US or other regulatory approvals?"
Changes Regulatory Teams Need on Their Radar
A New International Reliance Pathway (IRP)
The single most transformative element of the draft Regulations is the International Reliance Pathway.
The proposed framework would provide routes for certain medical devices that have already undergone regulatory assessment by recognised overseas regulators, including regulators in:
Australia;
Canada; and
the United States.
The objective is to reduce unnecessary duplication of regulatory assessment while maintaining UK oversight.
The IRP is reliance, not automatic recognition. Manufacturers still need UK labelling, UDI registration, a UK Responsible Person, GB device registration, and full post-market vigilance compliance, and the MHRA retains the right to request supplementary UK-specific clinical or performance data where a device differs materially from the version approved abroad.
Predetermined Change Control Plans (PCCPs) for AI and Software
For Software as a Medical Device and AI-enabled products, the draft Regulations formally introduce PCCPs - allowing manufacturers to pre-specify anticipated future modifications (performance tuning, cybersecurity patches, limited algorithm refinements) at the time of initial submission, rather than triggering re-certification for every update. This mirrors an approach already familiar to companies with FDA PCCP experience and is intended to make regulatory oversight compatible with continuous software deployment.
However, the PCCP provisions should not be interpreted as a general exemption from change-control requirements. Their application depends on the device, classification and applicable conformity-assessment route.
Manufacturers should therefore begin reviewing:
software change-control procedures;
software architecture and modularity;
anticipated algorithm modifications;
cybersecurity updates;
performance monitoring;
risk-management controls;
clinical/performance implications of planned changes; and
alignment between the PCCP and PMS activities.
IVD Classification Moves to a Risk-Based A–D Model
The UK's legacy IVD framework is being replaced with the same four-tier, risk-based structure used under the EU IVDR: Class A (lowest risk) through Class D (highest risk).
Many self-certified legacy IVDs are expected to require Approved Body review for the first time.
Manufacturers should begin by:
reassessing the intended purpose of each IVD;
mapping each product against the proposed UK classification rules;
identifying products whose classification may change;
assessing the resulting conformity-assessment implications; and
reviewing performance evaluation and PMS documentation.
Strengthening Post-Market Surveillance
The UK's enhanced medical device PMS framework already introduced significant changes from June 2025, including strengthened vigilance reporting and trend-monitoring requirements.
The 2026 reforms should therefore be viewed as part of an ongoing strengthening of the UK's lifecycle regulatory framework.
For manufacturers still relying heavily on manual spreadsheets or fragmented complaint systems, the increasing regulatory emphasis on timely signal detection creates a strong case for more structured PMS processes.
Custom-Made and Implantable Devices Face New Controls
The proposed reforms introduce additional controls for certain custom-made implantable devices.
In particular, manufacturers of Class IIb and Class III custom-made implantable devices would be subject to additional quality-system requirements, including certification by a UK Approved Body.
The draft Regulations also introduce implant-card requirements for specified implantable devices, with defined exclusions.
The proposed information includes key device identification and manufacturer information intended to support patient and healthcare-professional access to relevant implant information.
Manufacturers of implantable devices should therefore review:
device traceability;
UDI implementation;
implant-card processes;
document retention;
PMS records; and
QMS certification requirements.
What Regulatory and Quality Teams Should Do Now
Map your GB market-access strategy: Assess whether each device is likely to use CE recognition, UK-specific conformity assessment or the proposed International Reliance Pathway.
Reassess device classification: Review medical device and IVD classifications, with particular attention to software, AI-enabled products and higher-risk IVDs.
Review software change controls: For applicable software devices, assess whether a Predetermined Change Control Plan could support the management of anticipated future modifications.
Stress-test PMS and vigilance systems: Ensure processes can support timely incident assessment, trend analysis, signal detection, reporting and CAPA.
Evaluate international reliance opportunities: Manufacturers holding FDA, Health Canada or TGA approvals should assess potential eligibility for the proposed reliance routes.
Review implantable-device controls: Assess UDI, traceability, implant-card, document-retention and, where applicable, Approved Body QMS certification requirements.
Maintain regulatory watch: Continue monitoring the MHRA's final legislation, implementation guidance and timelines, recognising that the draft provisions may change before implementation.
Outlook
The UK's medical device regulatory reform programme represents a significant evolution of the GB regulatory framework. However, the direction should not be characterised simply as "CE out, UKCA in."
Instead, the emerging model combines: a distinct GB regulatory framework + continued/expanded CE recognition + international reliance + stronger lifecycle controls.
For manufacturers, this creates both opportunities and new strategic considerations. International reliance could reduce duplicated regulatory assessment for eligible products. PCCPs could provide greater predictability for certain software changes. Risk-based IVD classification could bring the UK closer to internationally familiar regulatory models.
/Start mapping the potential impact now but base implementation decisions on the final legislation and MHRA guidance once issued.
Need An Expert Review
Optimus Compliance helps medical device manufacturers navigate UKCA and the UK’s evolving medical device regulatory framework by reviewing technical documentation, identifying compliance gaps, and preparing manufacturers for upcoming MHRA requirements.
Book a free consultation at
Comments